This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice. Conclusions: ...

When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...

Recommendations include use of ACE-I or ARB to slow CKD progression in patients with hypertension and albuminuria.

The U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) updated their 2019 clinical practice ...

Hydration is a surprisingly important diabetes health factor, and its even more important if you also have chronic kidney disease (CKD). CKD develops in 10 to 40 percent of people with type 2 diabetes ...

Patients with hyperglycemic crisis at type 2 diabetes diagnosis should be closely monitored for acute kidney injury and chronic kidney disease. The risk for chronic kidney disease (CKD) is higher for ...

The new type 2 diabetes treatment algorithm consensus statement from the American Association of Clinical Endocrinologists (AACE), running to 48 pages, has been published online and is available for ...

α-Glucosidase inhibitors 0.5–0.8 Weight neutral Frequent GI side effects, three times/day dosing, expensive Exenatide 0.5–1.0 Weight loss Injections, frequent GI side effects, expensive, little ...